SYSTEMIC SCLEROSIS

This early-stage study is testing a new treatment called C-CAR168 for people with autoimmune diseases like multiple sclerosis, lupus, and myasthenia gravis that have not improved with standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab…

This Phase 3 trial tests whether the oral drug nerandomilast can slow disease progression in adults with systemic sclerosis (scleroderma). About 448 participants will be randomly assigned to receive either nerandomilast or a placebo twice daily for up to 4 years. Researchers will…

This first-in-human study tests the safety of a new drug called HBM7020. It will first be given to healthy volunteers at low doses, then to people with moderate to severe autoimmune diseases like lupus, rheumatoid arthritis, scleroderma, and Sjögren's disease. The goal is to see …

This early-phase trial tests an injection called KSVCBD, a type of CAR-T cell therapy, in 60 adults with severe autoimmune diseases like lupus and scleroderma. The goal is to see if it's safe and to get a first look at whether it might help control the disease. Participants recei…

This early-phase trial tests a single dose of universal (off-the-shelf) CAR-T cells in 30 adults with active autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's. The treatment targets CD19 and BCMA on immune cells to reset the faulty immune system. The…

This early-phase study tests a new treatment called BEN301, which uses specially engineered immune cells (CAR-Tregs) to calm overactive immune responses in people with autoimmune diseases like scleroderma, rheumatoid arthritis, lupus, and inflammatory muscle disease. The trial wi…

This early study tests a new treatment called CD19/BCMA CAR-T for people with severe autoimmune diseases like lupus and Sjögren's syndrome that haven't improved with standard care. The treatment involves taking a patient's own immune cells, modifying them to target specific immun…

This early-phase study tests a new mRNA therapy that targets CD19, a protein on immune cells, to treat autoimmune diseases like lupus and immune anemia. The treatment uses lipid nanoparticles to deliver mRNA that helps the body clear harmful B cells. About 47 participants aged 14…

This early study tests a new treatment called CD19 UCAR-T cells for people with autoimmune diseases like lupus, vasculitis, and Sjögren's syndrome. The therapy uses modified immune cells to target and calm the overactive immune system. The main goals are to check safety and see i…

This study tests a new treatment using CD19 CAR T-cells for people with severe autoimmune diseases that haven't improved with standard therapies. About 30 participants will receive a single dose of these engineered immune cells after chemotherapy. The goal is to see if it's safe …

This study looks at whether two substances in the blood, IL-6 and MMP-7, can help doctors diagnose and predict the course of a rare lung disease in children. Researchers will measure these markers in 60 children with immune-mediated interstitial lung disease and compare them to h…

This study aims to find the best way to share research results with people who have scleroderma, a rare autoimmune disease. About 128 participants will be randomly assigned to receive either an infographic or a plain-language summary of a study. They will then rate how complete, …

This study looks at whether a substance in the blood called catestatin is linked to heart and blood vessel problems in people with systemic sclerosis (scleroderma). Researchers will measure catestatin levels in 70 patients and compare them to healthy people. The goal is to see if…

This study will use an overnight sleep test (polysomnography) to measure breathing problems during sleep in 30 adults with systemic sclerosis (scleroderma). The goal is to find out how common sleep-disordered breathing is in this group. No treatment is given—this is purely an obs…

This study will use Doppler ultrasound to measure blood flow in the gut arteries of 74 people with systemic sclerosis (scleroderma) and compare them to healthy volunteers. The goal is to see if changes in blood flow relate to digestive symptoms and other organ problems. This is a…

This study will collect health information, samples, and data from 100 people in Luxembourg (800 total across Europe) who have rheumatoid diseases and are starting or changing treatment. Researchers hope to find patterns that can predict which treatments work best for each person…